Tag: communications

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Hims To Contact Him Directly To Discuss Their Options

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Centene To Contact Him Directly To Discuss Their Options

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Petco To Contact Him Directly To Discuss Their Options

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their Options

SAN DIEGO, Aug. 16, 2025 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Charter Communications, Inc. (NASDAQ: CHTR) securities, including purchasers of call options or sellers of put options between July 26, 2024 and July 24, 2025, inclusive (the “Class Period”), have until October 14, 2025 to seek appointment as lead plaintiff of the Charter Communications class action lawsuit. Captioned Sandoval v. Charter Communications, Inc., No. 25-cv-06747 (S.D.N.Y.), the Charter Communications class action lawsuit charges Charter Communications and certain of Charter Communications’ top executives with violations of the Securities Exchange Act of 1934.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In SelectQuote To Contact Him Directly To Discuss Their Options

   
- Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial

Accelerating cleantech economic growth and sustainability initiatives through innovation, collaboration and education

Joins Workhorse’s proven vehicles, manufacturing capabilities and national dealer network with Motiv’s diverse product portfolio and top fleet relationships

Jennifer Callahan, Chief Financial Officer, appointed Interim CEO

SOUTH SAN FRANCISCO, Calif., Aug. 15, 2025 (GLOBE NEWSWIRE) --  Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options to purchase an aggregate of 42,300 shares of the Company’s stock (the “Inducement Grant”) to newly hired employees on August 12, 2025 (the “Grant Date”), in connection with the commencement of employment.